As of yet, associations of sMR in obesity and diabetes have not been described, whereas sCD163 levels are increased in both obesity and type 2 diabetes and, hence, given that our cohort is both leaner and nondiabetic it may explain why our intervention with liraglutide does not reduce sCD163 levels. Here, CD163 is linked to type 2 diabetes mellitus.